Back to results
US 2026/0098087 A1Published application
Dosages of emactuzumab
AssigneeSynox Therapeutics UK Limited
InventorsRaymond BARLOW, Axel MESCHEDER, Michael CANNARILE, Georgina MENESES-LORENTE
Life of this patent
Estimating the term…
Abstract
The present invention relates to a treatment regime, including an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R) for use in the treatment of tenosynovial giant cell tumour (TGCT) in a subject, as well as associated uses and methods.
Claims19
(canceled)
A method for the treatment of tenosynovial giant cell tumour (TGCT) in a subject, according to a treatment regimen;
- wherein the treatment regimen comprises up to five treatment cycles of an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R);
- and,
- wherein a treatment cycle comprises one administration of about 200 mg to about 1,500 mg of the antibody or antigen-binding fragment, followed by an about 6-day to an about a 20-day period of rest.
(canceled)
(canceled)
Dependencies are inferred from the claim text.